INACTIVATION OF FREE AND CELL-ASSOCIATED HUMAN-IMMUNODEFICIENCY-VIRUS IN PLATELET SUSPENSIONS BY AMINOMETHYLTRIMETHYLPSORALEN AND ULTRAVIOLET-LIGHT

被引:16
|
作者
BENADE, LE
SHUMAKER, J
XU, Y
CHEN, X
DODD, RY
机构
[1] Developmental Virology and Genetics Group, Transmissible Diseases Department, Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross Blood Services, Rockville, Maryland, 20855
关键词
D O I
10.1046/j.1537-2995.1994.34894353463.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: It has previously been reported that 40 mu g per mL of aminomethyltrimethylpsoralen (AMT) plus 2.4 to 7.2 J per cm(2) of ultraviolet A (UVA) light inactivated 4 to 6 log(10) of several model viruses in platelet suspensions. This inactivation was achieved while satisfactory levels of platelet count, pH, morphology, aggregation, and hemostatic effectiveness were maintained. Study Design and Methods: The efficacy of this procedure for inactivating free and intracellular human immunodeficiency virus (HIV), including integrated proviral sequences, was studied. Results: The kinetics of inactivation for free HIV (4-5 log(10) kill with 1.2-4.8 J/cm(2)) were similar to those obtained for the previously studied viruses. For studies on cell-associated virus, H9 cells productively infected with HIV were added to platelet suspensions and treated with the above regimen of AMT and UVA. The phototreated cells were then cocultivated with uninfected H9 cells for 4 weeks and supernatants were assayed by enzyme-linked immunosorbent assay for HIV p24. No evidence of HIV replication was detectable for cells receiving as little as 2.4 J per cm(2) of UVA irradiation in the presence of AMT. Further, it has been demonstrated that stably integrated sequences from the HIV proviral env gene can no longer be amplified by polymerase chain reaction after 1.2 J per cm(2) of UVA (with 40 mu g/mL AMT) exposure. Conclusion: These data suggest that AMT and UVA is an effective antiviral treatment for free and cell-associated HIV in platelet suspensions. TRANSFUSION 1994;34:680-684.
引用
收藏
页码:680 / 684
页数:5
相关论文
共 50 条
  • [31] PACAP PREVENTS NEURONAL CELL-DEATH ASSOCIATED WITH THE ENVELOPE PROTEIN FROM THE HUMAN-IMMUNODEFICIENCY-VIRUS
    BRENNEMAN, DE
    ARIMURA, A
    [J]. REGULATORY PEPTIDES, 1992, 37 (03) : 321 - 321
  • [32] ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED T-CELL LYMPHOMA - EVIDENCE FOR HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1-ASSOCIATED T-CELL TRANSFORMATION
    HERNDIER, BG
    SHIRAMIZU, BT
    JEWETT, NE
    ALDAPE, KD
    REYES, GR
    MCGRATH, MS
    [J]. BLOOD, 1992, 79 (07) : 1768 - 1773
  • [33] Cell-Associated Human Immunodeficiency Virus (HIV) Ribonucleic Acid Has a Circadian Cycle in Males With HIV on Antiretroviral Therapy
    Stern, Jared
    Solomon, Ajantha
    Dantanarayana, Ashanti
    Pascoe, Rachel
    Reynaldi, Arnold
    Davenport, Miles P.
    Milush, Jeffrey
    Deeks, Steven G.
    Hartogensis, Wendy
    Hecht, Frederick M.
    Cockerham, Leslie
    Roche, Michael
    Lewin, Sharon R.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2021, 225 (10): : 1721 - 1730
  • [34] Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection
    Terrazas-Aranda, Katty
    Van Herrewege, Yven
    Hazuda, Daria
    Lewi, Paul
    Costi, Roberta
    Di Santo, Roberto
    Cara, Andrea
    Vanham, Guido
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) : 2544 - 2554
  • [35] FREE LIGHT-CHAINS OF IMMUNOGLOBULINS IN THE CEREBROSPINAL-FLUID OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1-INFECTED PATIENTS
    GALLO, P
    PICCINNO, MG
    DEROSSI, A
    PAGNI, S
    AMADORI, A
    CHIECOBIANCHI, L
    TAVOLATO, B
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1990, 26 (03) : 229 - 238
  • [36] Predictors of Cell-Associated Human Immunodeficiency Virus (HIV)-1 DNA Over 1 Year in Very Early Treated Infants
    Kuhn, Louise
    Paximadis, Maria
    Dias, Bianca Da Costa
    Shen, Yanhan
    Mncube, Sizanani
    Strehlau, Renate
    Shiau, Stephanie
    Patel, Faeezah
    Burke, Megan
    Technau, Karl-Gunter
    Sherman, Gayle
    Loubser, Shayne
    Abrams, Elaine J.
    Tiemessen, Caroline T.
    [J]. CLINICAL INFECTIOUS DISEASES, 2022, 74 (06) : 1047 - 1054
  • [37] Inactivation of human immunodeficiency virus type 1 (HIV-1) and mutagenicity testing in human platelet concentrates (PC) after treatment with a coumarin-based compound and long wavelength ultraviolet A light (UVA)
    SowemimoCoker, SO
    Park, S
    Yerram, NR
    Crandall, S
    Goodrich, RP
    [J]. BLOOD, 1995, 86 (10) : 3433 - 3433
  • [38] Independent levels of cell-free and cell-associated human immunodeficiency virus-1 in genital-tract secretions of clinically asymptomatic, treatment-naive African women
    Andréoletti, L
    Chomont, N
    Grésenguet, G
    Matta, M
    Longo, JD
    Carreno, MP
    Si-Mohamed, A
    Legoff, J
    Kazatchkine, MD
    Bélec, L
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (04): : 549 - 554
  • [39] RESTRICTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PRODUCTION IN A HUMAN ASTROCYTOMA CELL-LINE IS ASSOCIATED WITH A CELLULAR BLOCK IN REV FUNCTION
    NEUMANN, M
    FELBER, BK
    KLEINSCHMIDT, A
    FROESE, B
    ERFLE, V
    PAVLAKIS, GN
    BRACKWERNER, R
    [J]. JOURNAL OF VIROLOGY, 1995, 69 (04) : 2159 - 2167
  • [40] Partial efficacy of broadly neutralizing antibody PGT121 against cell-associated simian-human immunodeficiency virus (SHIV) infection
    Parsons, M.
    Lloyd, S.
    Center, R.
    Amarasena, T.
    Swiderek, K.
    Kent, S.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 629 - 629